BusinessUK-based Relation Therapeutics Limited and GSK have announced an expanded research collaboration focused on generating large-scale human cellular...
Read full article →
Researchers at Massachusetts General Hospital in Boston, working with colleagues at the Broad Institute of MIT and Harvard and Santa Monica,...
Plymouth Meeting, Pennsylvania-based Inovio Pharmaceuticals (Nasdaq: INO) announced the pricing of a USD 20 million underwritten public offering on July 29,...
Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Firefly Bio, Inc. for USD 1 billion in cash, adding the company's proprietary Firelink...
Vero Beach, Florida-based Processa Pharmaceuticals (Nasdaq: PCSA) has acquired Vidya Therapeutics, a private clinical-stage company developing VT-7208, a...
The US FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 against the effectiveness of deramiocel (CAP-1002) for the...
London and San Francisco-based Verdiva Bio Limited has dosed the first patient in a Phase I single ascending dose study of VRB-103, a once-weekly oral...
UK-based Iksuda Therapeutics has received US FDA clearance of its investigational new drug application for IKS04, a CA242-directed antibody-drug conjugate...
Biogen Inc. (Nasdaq: BIIB) Q2 2026 earnings call, held on July 29, 2026, centered on five imminent registrational readouts across lupus, antibody-mediated...
Scripps Research Institute has received a USD 1.62 million NIAID R01 grant to advance preclinical development of two novel small-molecule inhibitors...
Cambridge, Massachusetts-based Caldera Therapeutics has agreed to merge with Synlogic, Inc. (OTC: SYBX) in an all-stock transaction, with the combined...
San Francisco-based Adjuvia Therapeutics has closed an USD 8 million Series Seed financing to advance its lead mitochondrial disease therapy candidate,...
Vancouver-based AbCellera Biologics (Nasdaq: ABCL) has announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to discover and develop...
Irvine, California-based Qnovia, Inc. has secured a worldwide exclusive license to a preclinical antimicrobial peptide, designated D8, from the University...
New York-based LB Pharmaceuticals Inc (Nasdaq: LBRX) has announced a USD 150 million private placement, with the proceeds earmarked primarily to expand its...
China-based Hansoh Pharmaceutical Group (HKEX: 03692) announced that HS-20093, its proprietary B7-H3-directed antibody-drug conjugate, met the primary...
Systematic R&D and deal news. Daily.